TY - JOUR
T1 - Association of IL-2RA/CD25 with type 1 diabetes in the Belgian population
AU - Belgian Diabetes Registry
AU - Aminkeng, Folefac
AU - Weets, Ilse
AU - Van Autreve, Jan E
AU - Koeleman, Bobby P C
AU - Quartier, Erik
AU - Van Schravendijk, Chris
AU - Gorus, Frans K
AU - Van der Auwera, Bart J R
N1 - Copyright © 2010 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.
PY - 2010/12
Y1 - 2010/12
N2 - Our goals were to study the proposed association of IL-2RA /CD25 with type 1 diabetes in the Belgian population over a broad age range, and to explore possible correlations with disease phenotypes, immune markers, HLA-DQ, INS, and PTPN22. Patients (n = 1954), healthy controls (n = 2082), and families (n = 420) were genotyped for IL-2RA/CD25 rs41295061(C>A), HLA-DQ, INS-VNTR and PTPN22. IL-2RA/CD25 was associated with type 1 diabetes (χ(2) = 26.8, p < 0.001 for alleles and χ(2) = 29.6, p < 0.001 for genotypes). The C allele (odds ratios [OR] = 1.59) and C/C genotype (OR = 1.56) were identified as susceptibility variants, whereas the A allele (OR = 0.63), A/A genotype (OR = 0.14), and A/C genotype (OR = 0.69) as protective variants. IL-2RA/CD25 is associated with both early-onset and late-onset type 1 diabetes, but with a larger effect size in early-onset disease. There was a nonsignificant tendency toward transmission distortion (p = 0.063). Except a tendency toward younger age at onset in carriers of the C/C genotype, no correlations with disease phenotype, immune markers, HLA-DQ, INS and PTPN22 were observed. Also, the frequency of the susceptible genotype was higher in early-onset compared with late-onset TID patients (p = 0.015). In conclusion, IL-2RA/CD25 is associated with type 1 diabetes in the Belgian population, independently of disease phenotype and other biologic markers.
AB - Our goals were to study the proposed association of IL-2RA /CD25 with type 1 diabetes in the Belgian population over a broad age range, and to explore possible correlations with disease phenotypes, immune markers, HLA-DQ, INS, and PTPN22. Patients (n = 1954), healthy controls (n = 2082), and families (n = 420) were genotyped for IL-2RA/CD25 rs41295061(C>A), HLA-DQ, INS-VNTR and PTPN22. IL-2RA/CD25 was associated with type 1 diabetes (χ(2) = 26.8, p < 0.001 for alleles and χ(2) = 29.6, p < 0.001 for genotypes). The C allele (odds ratios [OR] = 1.59) and C/C genotype (OR = 1.56) were identified as susceptibility variants, whereas the A allele (OR = 0.63), A/A genotype (OR = 0.14), and A/C genotype (OR = 0.69) as protective variants. IL-2RA/CD25 is associated with both early-onset and late-onset type 1 diabetes, but with a larger effect size in early-onset disease. There was a nonsignificant tendency toward transmission distortion (p = 0.063). Except a tendency toward younger age at onset in carriers of the C/C genotype, no correlations with disease phenotype, immune markers, HLA-DQ, INS and PTPN22 were observed. Also, the frequency of the susceptible genotype was higher in early-onset compared with late-onset TID patients (p = 0.015). In conclusion, IL-2RA/CD25 is associated with type 1 diabetes in the Belgian population, independently of disease phenotype and other biologic markers.
KW - Adolescent
KW - Adult
KW - Age of Onset
KW - Autoantibodies/blood
KW - Belgium/epidemiology
KW - Child
KW - Diabetes Mellitus, Type 1/epidemiology
KW - Female
KW - Genetic Predisposition to Disease
KW - Genotype
KW - HLA-DQ Antigens/genetics
KW - Humans
KW - Interleukin-2 Receptor alpha Subunit/genetics
KW - Male
KW - Phenotype
KW - Polymorphism, Genetic
KW - Protein Tyrosine Phosphatase, Non-Receptor Type 22/genetics
KW - Young Adult
U2 - 10.1016/j.humimm.2010.09.006
DO - 10.1016/j.humimm.2010.09.006
M3 - Article
C2 - 20849903
SN - 0198-8859
VL - 71
SP - 1233
EP - 1237
JO - Human Immunology
JF - Human Immunology
IS - 12
ER -